# Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

> **NCT06467617** · PHASE2 · RECRUITING · sponsor: **Beijing Chest Hospital, Capital Medical University** · enrollment: 35 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab

## Key facts

- **NCT ID:** NCT06467617
- **Lead sponsor:** Beijing Chest Hospital, Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06467617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06467617, "Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06467617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*